University of Queensland researchers have identified that HER3 is overexpressed in brain metastases from breast cancer patients. They have shown inhibition of HER3 signalling significantly reduces tumour growth and burden in vitro and in vivo by the addition of the neutralizing antineuregulin antibody (HER3 ligand inhibitor) or inhibitors of other HER members involved in HER3 signalling, including Tykerb® (an EGFR and HER2 kinase inhibitor) or traztuzumab. This discovery offers the potential to treat breast cancer brain metastases by targeting HER3 and/or HER3 signalling, including the inhibition of one or more members of the epidermal growth factor receptor family.

• Collaboration
• Licenceⁱ